JP2023549067A - Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用 - Google Patents

Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用 Download PDF

Info

Publication number
JP2023549067A
JP2023549067A JP2023525485A JP2023525485A JP2023549067A JP 2023549067 A JP2023549067 A JP 2023549067A JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023525485 A JP2023525485 A JP 2023525485A JP 2023549067 A JP2023549067 A JP 2023549067A
Authority
JP
Japan
Prior art keywords
yang
antibody
impi
domain
domain sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549067A5 (https=
Inventor
ポール・ケラム
アン・パルサー
フォルカー・ゲルマシェウスキー
サイモン・ジェームズ・ワトソン
ベンジャミン・デイヴィッド・グリムショー
シュペラ・ビンター
ヤロスロウ・ミハル・サリ
マルゴ・ビヨー
ロバート・ローランズ
アイシュワリヤー・クリシュナ
ホアン－チュン・リン
チェン－ユエン・ヤン
リー－イン・リョウ
Original Assignee
カイマブ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイマブ・リミテッド filed Critical カイマブ・リミテッド
Publication of JP2023549067A publication Critical patent/JP2023549067A/ja
Publication of JP2023549067A5 publication Critical patent/JP2023549067A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
JP2023525485A 2020-10-27 2021-10-27 Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用 Pending JP2023549067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2017058.5 2020-10-27
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549067A true JP2023549067A (ja) 2023-11-22
JP2023549067A5 JP2023549067A5 (https=) 2024-11-05

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525485A Pending JP2023549067A (ja) 2020-10-27 2021-10-27 Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用

Country Status (12)

Country Link
US (1) US20250026813A1 (https=)
EP (1) EP4237442A1 (https=)
JP (1) JP2023549067A (https=)
KR (1) KR20230113295A (https=)
CN (1) CN117396501A (https=)
AU (1) AU2021369450A1 (https=)
CA (1) CA3199594A1 (https=)
CO (1) CO2023006684A2 (https=)
GB (1) GB202017058D0 (https=)
IL (1) IL302244A (https=)
MX (1) MX2023004869A (https=)
WO (1) WO2022090353A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
US12496470B2 (en) 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
EP4630447A2 (en) * 2022-12-09 2025-10-15 Abwiz Bio, Inc. Antibodies or fragments thereof for sars-cov-2 and variants thereof
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIODRUGS, vol. 21, no. 3, JPN6025050482, 2007, pages 145 - 156, ISSN: 0005753921 *
BIORXIV, JPN6025050479, August 2020 (2020-08-01), pages 1 - 45, ISSN: 0005753924 *
PNAS, vol. 79, JPN6025050481, 1982, pages 1979 - 1983, ISSN: 0005753922 *
SCIENCE, vol. 369, JPN6025050480, August 2020 (2020-08-01), pages 1014 - 1018, ISSN: 0005753923 *
SCIENCE, vol. 369, JPN6025050483, August 2020 (2020-08-01), pages 1010 - 1014, ISSN: 0005753920 *
SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 5, no. 212, JPN6025050484, September 2020 (2020-09-01), pages 1 - 12, ISSN: 0005753919 *

Also Published As

Publication number Publication date
WO2022090353A1 (en) 2022-05-05
KR20230113295A (ko) 2023-07-28
MX2023004869A (es) 2023-06-01
CO2023006684A2 (es) 2023-05-29
AU2021369450A1 (en) 2023-06-22
AU2021369450A9 (en) 2025-04-10
US20250026813A1 (en) 2025-01-23
IL302244A (en) 2023-06-01
GB202017058D0 (en) 2020-12-09
CA3199594A1 (en) 2022-05-05
CN117396501A (zh) 2024-01-12
EP4237442A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
JP2023549067A (ja) Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用
ES2973425T3 (es) Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
KR20220164465A (ko) Sars-cov-2에 대한 항체 및 이의 사용 방법
US10273288B2 (en) Neutralizing antibodies to Ebola virus glycoprotein and their use
CN118829653A (zh) 用tl1a抑制剂和il23抑制剂的组合治疗炎性疾病的方法
US20240270828A1 (en) Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof
US20260062464A1 (en) Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
JP6954696B1 (ja) ＳＡＲＳ−ＣｏＶ−２のＳｐｉｋｅタンパク質の変異体およびその用途
JP2024533166A (ja) 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
AU2021338380A1 (en) Human monoclonal antibodies to SARS-CoV-2 and use thereof
RU2832025C1 (ru) Антитела против sars-cov-2 и способы их применения
RU2832110C1 (ru) Поливалентная векторная вакцина hvt
WO2022162097A2 (en) Antibodies and uses thereof
CN116916958A (zh) 用于sars-cov-2感染的抗体疗法
WO2023034871A1 (en) High concentration antibody therapies for sars-cov-2 infection
CN119213024A (zh) hMPV抗体及其用途
HK40057872A (en) Neutralizing antibodies to ebola virus glycoprotein and their use
WO2023201256A1 (en) High dose antibody therapies for sars-cov-2 infection
WO2024068996A1 (en) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2023199943A1 (ja) コロナウイルス感染症を処置することに用いられる抗体
CN117751137A (zh) 抗sars-cov-2抗体和其使用方法
IT202300015579A1 (it) Anticorpi contro covid-19 e altri coronavirus umani

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401